business presentation - business...today • why pbi • what is the felder doctrinetm • pbi...

Business Presentation

September 2012

©2012 confidential and proprietary. All rights reserved

today• why PBI

• what is The Felder DoctrineTM

• PBI business model

• sequential dialysis and Feldetrex

• medical team

• timeline


According to World Health Organization (WHO) chronic diseases, such as heart disease, stroke,

cancer, chronic respiratory diseases and diabetes, are by far the leading cause of mortality in the

world, representing 63% of all deaths out of the 36 million people who died in 2008.

To date there is still no cure!



In order to grow, thrive and metastasize, cancer tissue is dependent upon the presence of certain molecular compounds: cytokines, antigenic proteins, tumorigenesis proteins, signaling proteins, etc. If these are physically removed the cancer can not thrive or metastasize.

Mitchell S. Felder, M.D.

Dr. James WatsonFinley, A. (2010, 27 11). The Wall Street Journal.

All of these cells, he notes, secrete a protein—interleukin-6—and in lab experiments, adding

interleukin-6 to lung cancer cells that had been controlled by anti-cancer drugs made them resistant

to the treatments.

Thus the key to curing cancer may be finding a drug that blocks interleukin-6. "While this would be

wonderful if it turns out to be true," he says, he doesn't know if it is and he concedes, "it's not

conventional wisdom .“

–Interview on November 27, 2010 with Dr. James Watson (Finley, 2010). Dr. Watson, identified DNA’s ability to create life

through its double helical structure and its information-coding sequences. The discovery of DNA’s double helix was an

extensive undertaking of world-historic importance.

Physical removal of the

pathophysiologic basis

of the disease.

The Felder DoctrineTM


The PBI Business model

PBI

DOD **UTEP *

1. Use the tripod approach

2. Coordinate our IP with the lab services of a large research based university (UTEP’s $45 million lab)

3. And then add the remarkable services of the Department of Defense (DOD) with their large, unequalled power of animal model creation and clinical testing

* Collaborative Agreement signed April 2012 with University of Texas at El Paso** Cooperative Research and Development Agreement (CRADA) pending with the Department of Defense (DOD)

4. License Big Pharma selling rights to individual diseases while retaining the largest royalties possible thru aggressive competitive bidding.


Sequential dialysis

• Our proprietary Sequential-Dialysis Technique is a methodology for the removal of those molecules which are harmful and responsible for causing diseases. – Extracorporeal (outside the body)process to prevent the myriad of

severe side effects which are normally encountered. – The methodology can be used for:

• The prevention of cancer metastasis• Directly attacking the causation of intractable seizures• Preventing the death of anterior motor neurons in ALS• Preventing the cause of the neuropathological changes in Alzheimer's Disease• Traumatic Brain Injury • Eradicating the causations of Infectious Diseases

The methodology involved in this technique is largely unexplored and has been described by scientists as the "wild west" of modern medicine. Consequently, our first entry into this market carries significant obstacles before reaching the

significant opportunities of a $2 trillion industry.


Feldetrex™

• Feldetrex™: A proprietary combination of generic medications which is believed to reduce the symptomology of Multiple Sclerosis, Fibromyalgia, and Traumatic Brain Injury.– The dosages, combinations, and ingredients of Feldetrex™ allow it to be

efficacious yet have lower side effects.

– Our patent attorneys confirm that our Feldetrex™ drug has proprietary rights. In this way, Feldetrex™ is similar to Viagra, which was a proprietary cardiac drug prior to its current use and ownership by Pfizer. Consequently, we have one pending patent application for our Feldetrex™ drug.

– Feldetrex™ does not compete with FDA approved medications for Multiple Sclerosis, Fibromyalgia, or Traumatic Brain Injury but, rather, is an add-on drug to decrease the symptomology in those conditions.


Press Releases will be issued at least once/month.

Articles to be authored in daily and monthly periodicals, medical journals.

Participate in symposiums, seminars, and conferences to further broadcast our company position, strategy, and

scientific developments

---NO COMPETITION---

Pills, chemotherapy, surgery, etc are ineffective products/processes, which have demonstrate little or no positive

results in almost all chronically ill patients.

*This is the typical course of action used by Biotech firms targeting these diseases.

Marketing and Sales

Competition


Goals and Objectives for Cancer Treatment

Goals and Objectives for Alzheimer’s Disease and Traumatic Brain Injury

Insert own your picture


Use Sequential Dialysis to remove unwanted proteins and amino acids that cause plaque and tangles in the

brain by utilizing the premise of The Felder DoctrineTM

Kill cancer cells via protein reduction through the

utilization of Sequential Dialysis and The Felder

DoctrineTM

December 2010-Assembled BoD., which includes the Doctor, 2 attorneys, and individuals previously holding officer positions for public companies.

January 2011-Begin process of “going public”.

May 2012 –PBI and UTEP sign Collaborative Agreement: Aphaeresis Selective Depletion of Small Reactive Molecules and Pathogens that Involves a Novel Treatment of Brain Injury (TBI), Chronic Pain Syndrome, Fibromyalgia, Multiple Sclerosis, Amyotrophic, Lateral Sclerosis (ALS or Lou Gehrig’s disease), Blood Sepsis, Cancer, Heart Attacks and Strokes.

August 2012 –•Mutual Non-Disclosure Agreement with UTEP, PBI, and US Army Clinical Investigation Regulatory Office (CIRO).•Begin primary fundraising for laboratory development and clinical testing. Targeting private consortiums, institutional funds, grants, strategic partnerships, and philanthropic donations.

•BIEI opens at $1.01

December 2010 - PBI incorporated in Nevada

PBI Timeline

March 2012 –Dr. Mitchell Felder meets with Dr. Robert A. Kirken, Ph.D. Professor and Chair, Department of Biological Sciences at the University of Texas at El Paso (UTEP).

April 2012 –

UTEP demonstrates data to support Proof of Concept: Selective Depletion of Small Reactive

Molecules.

June 2012 –UTEP presents Scope of Work

Agreement for the Pre-clinical

Development of Premier Biomedical

Therapeutic Strategies.

July 2012 –

• PBI and UTEP sign Scope of Work Agreement.

•Received a letter of intent from William Beaumont Army Medical Center (WBAMC) stating their desire to join the consortium with their primary expertise in animal and clinical testing

2009Dr. Felder develops the theories that make the Felder Doctrine. Patents written and submitted



Safe Harbor Notice Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates and assumptions made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.

Contact Information:

Richard T. Najarian Chief Investment

Officer

(248) 709-9878

business presentation - business...today • why pbi • what is the felder doctrinetm • pbi...

Documents